Ugro Capital: Order of final hearing date schedule for 20th November 2026, under the scheme of amalgamation
Ugro Capital (UGROCAP) filed a disclosure titled "Order of final hearing date schedule for 20th November 2026, under the scheme of amalgamation". The company is valued at about ₹1,197 crore.
What happened
Ugro Capital (UGROCAP) filed a disclosure with the exchanges on 22 October 2026 at 05:21 PM titled "Order of final hearing date schedule for 20th November 2026, under the scheme of amalgamation".
Company snapshot
Ugro Capital is a small-cap company, with a market value of about ₹1,197 crore.
The stock last traded at ₹77.08, against a 52-week range of ₹76.3–₹189.9 (59.4% below the high).
Before this filing the shares had moved −6.7% over the month and −19.1% over three months. Average daily turnover over the last 20 sessions was about ₹1.87 crore.
Promoters held 2.88% at the end of Q1 FY27, up 0.89% points from the previous quarter. Foreign institutions owned 5.45% and domestic institutions 1.85%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 414 | 34.1 | 3.61 |
| Q2 FY26 | 455 | 43.3 | 3.79 |
| Q3 FY26 | 461 | 46.3 | 3.25 |
| Q4 FY26 | 607 | 51.1 | 3.35 |
| Q1 FY27 | 497 | 67.9 | 4.44 |
What history shows
This is not the company's first m&a disclosure: BCEIE has 6 earlier filings of this kind on record since May 2026.
After those filings, the stock fell 1.5% on average the next trading day and was down 3.3% on average after five days (6 filings with price data).
Market-wide, 2,120 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 18 Aug 2026 | M&A | −4.2% | −4.1% |
| 14 Aug 2026 | Dispatch of notices for convening separate meetings of Equity… | −2.7% | −5.5% |
| 12 Aug 2026 | Receipt of the certified copy of NCLT Order dated 6th August 2026 | +0.1% | −6.7% |
| 7 Aug 2026 | M&A | +0.6% | −2.5% |
| 17 Jul 2026 | Intimation of filing of Company Application (Scheme of Amalgamation)… | −0.2% | −1.1% |
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
- 5 November 2026: Board meeting — Financial Results/Other business matters.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.